

3Q 2020 FINANCIAL RESULTS

Financial Summary ¹

\$240M
Net Sales

\$0.38
Adjusted Diluted EPS


67%
Adjusted Gross Margin

13%
Adjusted Operating Margin


“During the third quarter, we remained focused on execution. The sequential improvement in all businesses was led by our growth drivers. We recognize there is more work to be done, and the team is operating to deliver on our growth drivers and strategic priorities. We believe these efforts will enable us to most effectively serve the needs of our customers and patients.”

– Damien McDonald, CEO of LivaNova

Sales Summary ²



- Neuromodulation
- Cardiovascular



| | | |
|-----|--------|-------|
| US | \$129M | ↓ 7% |
| EU | \$48M | ↓ 8% |
| ROW | \$63M | ↓ 21% |

Other Highlights



Continued Sequential Improvement Across all Segments

driven by U.S. performance

>90%

Organic Growth in Advanced Circulatory Support

driven by LifeSPARC™ launch

Strategic Priorities

Core Growth

- Expand the go-to-market initiative for U.S. Epilepsy
- ACS growth of at least 30% in 2020 & at least 20% in 2021

Pipeline Execution

- Achieve key study milestones in:
 - RECOVER and ANTHEM HFrEF
- Advance next-generation HLM

Operational Excellence

- Drive margin expansion
- Improve cash generation

ACS: Advanced Circulatory Support
HLM: Heart-Lung Machine



2020 Full-Year Guidance ³

Net Sales
-17% to -7%



Adjusted Diluted EPS
\$1.15 - \$1.35



¹ Adjusted financial measures are non-GAAP measures and exclude specified items as described and reconciled in the "Reconciliation of GAAP to non-GAAP Financial Measures" contained on the back of this document. All EPS measures in this document refer to diluted EPS from continuing operations. ² Unless otherwise noted, all sales growth rates in this document reflect constant-currency sales growth, which eliminates the effects of foreign currency fluctuations. Constant-currency growth, a non-GAAP financial measure, measures the change in sales between current and prior-year periods using average exchange rates in effect during the applicable prior-year period. ³ LivaNova calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For example, forward-looking net sales growth projections are estimated on a constant-currency basis and exclude the impact of foreign currency fluctuations. Forward-looking non-GAAP adjusted diluted earnings per share guidance exclude other items such as, but not limited to, stock-based compensation costs, changes in fair value of contingent consideration arrangements and product remediation costs that would be included in comparable GAAP financial measures. The most directly comparable GAAP measure for constant-currency net sales and adjusted diluted earnings per share are net sales and earnings per share, respectively. However, non-GAAP financial adjustments on a forward-looking basis are subject to uncertainty and variability as they are dependent on many factors, including but not limited to, the effect of foreign currency exchange fluctuations, impacts from potential acquisitions or divestitures, gains or losses on the potential sale of businesses or other assets, restructuring costs, merger and integration activities, changes in fair value of contingent consideration arrangements, product remediation costs and the tax impact of the aforementioned items, tax law changes or other tax matters. Accordingly, reconciliations to the most directly comparable forward-looking GAAP financial measures are not available without unreasonable effort.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES – UNAUDITED

Three Months Ended September 30, 2020

| | GAAP Financial Measures | Merger and Integration Expenses (A) | Restructuring Expenses (B) | Depreciation and Amortization Expenses (C) | Product Remediation Expenses (D) | Non-recurring Legal and Contingent Consideration (E) | Stock-based Compensation Costs (F) | Certain Tax Adjustments (G) | Certain Interest Adjustments (H) | Financing Transactions (I) | Adjusted Financial Measures |
|-------------------------------------|-------------------------|-------------------------------------|----------------------------|--|----------------------------------|--|------------------------------------|-----------------------------|----------------------------------|----------------------------|-----------------------------|
| Gross Margin | 63.5% | -- | -- | 0.1% | 0.5% | 2.2% | 0.2% | -- | -- | -- | 66.5% |
| Operating Margin | (3.1%) | 0.5% | (0.1%) | 4.7% | 0.5% | 7.8% | 3.3% | -- | -- | -- | 13.4% |
| Diluted EPS – Continuing Operations | (\$0.30) | \$0.02 | (\$0.01) | \$0.20 | \$0.02 | \$0.38 | \$0.15 | (\$0.05) | \$0.07 | (\$0.10) | \$0.38 |

Three Months Ended September 30, 2019

| | GAAP Financial Measures | Merger and Integration Expenses (A) | Restructuring Expenses (B) | Depreciation and Amortization Expenses (C) | Product Remediation Expenses (D) | Non-recurring Legal, Contingent Consideration and Other Reserves (E) | Stock-based Compensation Costs (F) | Certain Tax Adjustments (G) | Certain Interest Adjustments (H) | Acquisition Costs (J) | Adjusted Financial Measures |
|-------------------------------------|-------------------------|-------------------------------------|----------------------------|--|----------------------------------|--|------------------------------------|-----------------------------|----------------------------------|-----------------------|-----------------------------|
| Gross Margin | 66.8% | -- | -- | 0.2% | 1.1% | 1.9% | -- | -- | -- | -- | 70.1% |
| Operating Margin | 9.6% | 2.5% | 0.3% | 4.5% | 1.1% | (3.2%) | 3.2% | -- | -- | (0.1%) | 17.8% |
| Diluted EPS – Continuing Operations | \$0.66 | \$0.11 | \$0.01 | \$0.18 | \$0.04 | (\$0.09) | \$0.13 | (\$0.24) | \$0.04 | (\$0.01) | \$0.84 |

GAAP results include:

- (A) Merger and integration expenses related to our legacy companies and recent acquisitions
 - (B) Restructuring expenses related to organizational changes
 - (C) Includes depreciation and amortization associated with purchase price accounting
 - (D) Costs related to the 3T Heater-Cooler remediation plan
 - (E) Three-month period ended September 30, 2020 includes 3T Heater-Cooler litigation provision, legal expenses primarily related to 3T Heater-Cooler defense, settlements and other matters, remeasurement of contingent consideration related to acquisitions. Three-month period ended September 30, 2019 primarily relates to contingent consideration related to acquisitions, legal expenses related to 3T Heater-Cooler defense and other matters and insurance recovery.
 - (F) Non-cash expenses associated with stock-based compensation costs
 - (G) Primarily relates to discrete tax items and the tax impact of intercompany transactions
 - (H) Three-month period ended September 30, 2020 primarily relates to non-cash interest expense on our Senior Secured Term Loan and Cash Exchangeable Senior Notes, intellectual property migration and interest reversed upon the settlement of a tax litigation matter. Three-month period ended September 30, 2019 primarily relates to intellectual property migration, interest related to 3T Heater-Cooler litigation settlement and other non-recurring impacts to interest expense.
 - (I) Costs associated with our June 2020 financing transactions, including the mark-to-market adjustment for the exchangeable option feature and capped call derivatives
 - (J) Costs related to acquisitions
- * Numbers may not add up precisely due to rounding.

NET SALES: COMPARISON OF ACTUAL RESULTS TO CONSTANT CURRENCY – UNAUDITED ⁽¹⁾

(U.S. dollars in millions)

| Business / Product Line | Three Months Ended September 30, | | % Change at Actual Currency Rates | % Change at Constant-Currency Rates |
|-------------------------|----------------------------------|-------|-----------------------------------|-------------------------------------|
| | 2020 | 2019 | | |
| Cardiovascular | 140.9 | 155.4 | (9.4%) | (10.3%) |
| Neuromodulation | 98.4 | 112.5 | (12.6%) | (12.6%) |
| Other | 0.8 | 0.6 | 24.3% | 18.5% |
| Total Net Sales | 240.1 | 268.6 | (10.6%) | (11.2%) |

| Region | Three Months Ended September 30, | | % Change at Actual Currency Rates | % Change at Constant-Currency Rates |
|-----------------|----------------------------------|-------|-----------------------------------|-------------------------------------|
| | 2020 | 2019 | | |
| US | 128.9 | 138.4 | (6.9%) | (6.9%) |
| Europe | 48.5 | 50.2 | (3.4%) | (8.1%) |
| Rest of World | 62.7 | 79.9 | (21.6%) | (20.6%) |
| Total Net Sales | 240.1 | 268.6 | (10.6%) | (11.2%) |

(1) Constant-currency growth, a non-GAAP financial measure, measures the change in sales between current and prior-year periods using average exchange rates in effect during the applicable prior-year period. The sales results presented are unaudited. Numbers may not add up or recalculate precisely due to rounding.